Chitosan based surface modulation of core-shell nanoparticles for oral delivery of exenatide via balancing mucus penetration and cellular uptake
GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition, such as the following: Type 2 diabetes High blood pressure High cholesterol Obstructive sleep apnea Cardiovascular disease that increases the risk of heart attack or stroke MASH, or metabolic dysfunctionassociated steatohepatitis, a form of liver inflammation Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, notes that qualifying for the medication based on heart disease aloneoften necessary for insurance coveragecan be challenging
Some of the best strategies include changing your eating habits, hydrating wisely, staying upright after eating, using anti-nausea remedies, and following a titration schedule
It also requires you to have commercial insurance
What should I expect after a circumferential reduction treatment
